Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2017 May 9:11:1409-1416.
doi: 10.2147/DDDT.S130050. eCollection 2017.

Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers

Tae-Eun Kim  1 , Na Ha  2 , Yunjeong Kim  2 , Hyunsook Kim  1 , Jae Wook Lee  3 , Ji-Young Jeon  2 , Min-Gul Kim  2   4
Affiliations
Controlled Clinical Trial

Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers

Tae-Eun Kim et al. Drug Des Devel Ther. .

Abstract

Previous in vitro studies have demonstrated the inhibitory effect of green tea on drug transporters. Because rosuvastatin, a lipid-lowering drug widely used for the prevention of cardiovascular events, is a substrate for many drug transporters, there is a possibility that there is interaction between green tea and rosuvastatin. The aim of this study was to investigate the effect of green tea on the pharmacokinetics of rosuvastatin in healthy volunteers. An open-label, three-treatment, fixed-sequence study was conducted. On Day 1, 20 mg of rosuvastatin was given to all subjects. After a 3-day washout period, the subjects received 20 mg of rosuvastatin plus 300 mg of epigallocatechin-3-gallate (EGCG), a major ingredient of green tea (Day 4). After a 10-day pretreatment of EGCG up to Day 14, they received rosuvastatin (20 mg) plus EGCG (300 mg) once again (Day 15). Blood samples for the pharmacokinetic assessments were collected up to 8 hours after each dose of rosuvastatin. A total of 13 healthy volunteers were enrolled. Compared with the administration of rosuvastatin alone, the concomitant use at Day 4 significantly reduced the area under the concentration-time curve from time 0 to the last measurable time (AUClast) by 19% (geometric mean ratio 0.81, 90% confidence interval [CI] 0.67-0.97) and the peak plasma concentration (Cmax) by 15% (geometric mean ratio 0.85, 90% CI 0.70-1.04). AUClast or Cmax of rosuvastatin on Day 15 was not significantly different from that on Day 1. This study demonstrated that co-administration of EGCG reduces the systemic exposure of rosuvastatin by 19%, and pretreatment of EGCG can eliminate that effect of co-administration of EGCG.

Keywords: EGCG; drug interaction; drug transporter; green tea; pharmacokinetics; rosuvastatin.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study design. Notes: Arrows indicate the single dose of rosuvastatin (20 mg oral). Blood samples were taken on Days 1, 4, and 15 for pharmacokinetics. Abbreviation: EGCG, epigallocatechin-3-gallate.
Figure 2
Figure 2
Plasma concentration–time profiles of rosuvastatin. Notes: ● rosuvastatin (Day 1); ☐ rosuvastatin + EGCG (Day 4); △ rosuvastatin + EGCG + EGCG pretreatment (Day 15). Abbreviation: EGCG, epigallocatechin-3-gallate.
Figure 3
Figure 3
Plot of individual pharmacokinetic parameters of rosuvastatin per the treatment. Notes: Day 1, rosuvastatin alone; Day 4, rosuvastatin + EGCG; Day 15, rosuvastatin + EGCG + EGCG pretreatment. (A) Cmax; (B) AUClast; and (C) AUCinf. Abbreviations: EGCG, epigallocatechin-3-gallate; Cmax, peak plasma concentration; AUClast, area under the concentration–time curve from time 0 to the last measurable time; AUCinf, area under the concentration–time curve extrapolated to infinity.
See this image and copyright information in PMC

References

    1. Werba JP, Misaka S, Giroli MG, et al. Overview of green tea interaction with cardiovascular drugs. Curr Pharm Des. 2015;21(9):1213–1219. - PubMed
    1. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer. 2009;9(6):429–439. - PMC - PubMed
    1. Amiot MJ, Riva C, Vinet A. Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review. Obes Rev. 2016;17(7):573–586. - PubMed
    1. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006;296(10):1255–1265. - PubMed
    1. Hartley L, Flowers N, Holmes J, et al. Green and black tea for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;6:CD009934. - PMC - PubMed

Publication types

MeSH terms